RT Journal Article
T1 Implementation of Recommendations for the Management of Psoriasis During Preconception, Pregnancy, Postpartum, Breastfeeding, and Perinatal Care.
T2 Implementación de las recomendaciones sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto, la lactancia y el cuidado perinatal en pacientes con psoriasis.
A1 Belinchón, I
A1 Armesto, S
A1 de la Cueva, P
A1 Ferrándiz, L
A1 Rivera Díaz, R
A1 Carrascosa, J M
K1 Breastfeeding
K1 Embarazo
K1 Fertilidad
K1 Fertility
K1 Implementación
K1 Implementation
K1 Lactancia
K1 Posparto
K1 Postpartum
K1 Pregnancy
K1 Psoriasis
K1 Recomendaciones
K1 Recommendations
AB To analyze degree of implementation of recommendations on the management of psoriasis during preconception, pregnancy, postpartum, breastfeeding, and perinatal care published by the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV). We designed a structured online survey consisting of closed questions. A link was emailed to all the members of the Psoriasis Working Group to collect their anonymous responses. We also collected sociodemographic, professional, and practice-related data related to the goals of the study and then compiled descriptive statistics to analyze the survey findings. We received 53 responses for analysis. Overall, 96% of respondents were familiar with the recommendations, but very few of them worked in multidisciplinary maternity care units or had access to specific protocols on the management of psoriasis before, during, and after pregnancy in their departments. Seventy percent of dermatologists regularly ask their patients about pregnancy plans, but only 46% ask both men and women. Women also receive more preconception advice than men (54% vs. 19%). Significant variations were observed in the type of advice given. Ninety percent of the dermatologists interrupt topical treatments during pregnancy, and nearly all suspend conventional systemic drugs with the exception of cyclosporin A. Most biologics are also being discontinued in the third trimester, with the exception of certolizumab pegol. Almost all the respondents indicated that they use topical treatments, phototherapy, and certolizumab pegol in breastfeeding mothers. The main barriers to implementing the working group's recommendations are a lack of time, a lack of support, and a lack of robust data. Although the AEDV psoriasis working group's recommendations are widely known, areas for improvement remain.
YR 2022
FD 2022-03-12
LK http://hdl.handle.net/10668/21872
UL http://hdl.handle.net/10668/21872
LA en
LA es
DS RISalud
RD Jun 1, 2025